Supporting MRD Availability

Adults with moderately to severely active Crohn disease can now start risankizumab with an on-body injector at home.

For all the advances in breast cancer, there remains unmet need for patients whose cancer progresses after treatment with antibody-drug conjugates (ADCs). In the final week of Breast Cancer Awareness Month, AJMC® looks at an investigational vaccine approach that could come after ADCs, offering patients a low-toxicity regimen.

Hiddo Heerspink, PhD, discusses finerenone data in type 1 diabetes, FSGS and IgA nephropathy, and open questions on sequencing CKD therapies.